Compass Therapeutics to Participate in Upcoming May Investor Events
Compass Therapeutics
BOSTON, May 06, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics, today announced that the Company will participate in the following investor events during the month of May.
Details are as follows:
The Citizens Life Sciences Conference
Location: New York, NY
Date: Thursday, May 8, 2025
Time: 1:30 PM ET
Webcast Link: https://wsw.com/webcast/jmp65/cmpx/1692592
H.C. Wainwright 3rd Annual BioConnect Investor Conference at NASDAQ
Location: New York, NY
Date: Tuesday, May 20, 2025
Time: 11:30AM ET
Webcast Link: https://journey.ct.events/view/29729b86-5109-46dc-a93b-1cf3560aa9a1
Virtual/Replay availability: Presentations will be archived for 90 days on Compass' Events page.
About Compass Therapeutics
Compass Therapeutics, Inc. is a clinical-stage oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. Compass's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth. The company pipeline of novel product candidates is designed to target multiple critical biological pathways required for an effective anti-tumor response. These include modulation of the microvasculature via angiogenesis-targeted agents, induction of a potent immune response via activators on effector cells in the tumor microenvironment, and alleviation of immunosuppressive mechanisms used by tumors to evade immune surveillance. Compass plans to advance its product candidates through clinical development as both standalone therapies and in combination with proprietary pipeline antibodies based on supportive clinical and nonclinical data. The company was founded in 2014 and is headquartered in Boston, Massachusetts. For more information, visit the Compass Therapeutics website at https://www.compasstherapeutics.com.
Investor Contact
ir@compasstherapeutics.com
Media Contact
Anna Gifford, Chief of Staff
media@compasstherapeutics.com
617-500-8099
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
31 minutes ago
- Yahoo
Echofree Daily Wellness Supplement Launches Nationwide: Simplicity-Focused Option for Auditory Wellness Introduced
Plant-Based Daily Supplement Introduced for Adults Seeking a Simple Addition to Their Ear Wellness Routine Denver, June 07, 2025 (GLOBE NEWSWIRE) -- A new daily wellness supplement called Echofree has officially launched across the United States, offering adults a convenient option to support their general auditory well-being through a plant-based routine. According to the company, Echofree is designed for individuals looking to take a proactive approach to auditory health as part of their everyday lifestyle. Formulated with a blend of naturally derived ingredients, the supplement aims to complement healthy habits and routines that support overall ear wellness. Unlike traditional methods that may involve hardware or advanced interventions, Echofree emphasizes ease of use with its once-daily format. The product's simplicity is a key aspect of its appeal, allowing users to incorporate it into existing wellness regimens without disruption. The company notes that Echofree may be of interest to individuals looking for natural lifestyle support in the context of environmental noise exposure, aging-related wellness needs, or general interest in ear health. Produced in U.S.-based facilities that follow current industry safety standards, the supplement reflects a growing market trend focused on transparency and user education. To help foster consumer trust, Echofree offers detailed labeling, educational resources, and a satisfaction guarantee. More information—including a full list of ingredients and ordering options—is available through the official website at: About EchoFree EchoFree is a U.S.-based wellness brand committed to supporting individuals with easy-to-use, lifestyle-friendly dietary supplements. The company emphasizes transparency, simplicity, and consumer education, with a focus on plant-based formulas produced in facilities that meet current industry manufacturing standards. Media Contact: Company: EchoFreeAddress: 19655 E 35th Dr #100, Aurora, CO 80011Email: support@ Phone Support: (888) 540-0856 SOURCE: EchoFree CONTACT: Company: EchoFree Address: 19655 E 35th Dr #100, Aurora, CO 80011 Email: support@ Order Phone Support: (888) 540-0856Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
ProDentim Oral Probiotic Supplement Gains Attention for Supporting Healthy Teeth and Gums
Probiotic-Based Dental Supplement Offers a New Approach to Supporting Oral Microbiome and Gum Health New York, June 07, 2025 (GLOBE NEWSWIRE) -- A new dental health support supplement, ProDentim, is emerging as a potential option for consumers seeking to enhance their oral microbiome. Designed to promote overall gum health and fresh breath, ProDentim is available through its official website at According to publicly available details, ProDentim is formulated to support a balance of beneficial bacteria in the mouth. The product is presented as a chewable supplement and is marketed toward individuals interested in improving dental hygiene and maintaining healthy gums naturally. Although individual results may vary, consumers are encouraged to explore ProDentim as part of their wellness routine after reviewing full product information and disclosures provided on the manufacturer's website. The supplement has gained popularity through online wellness communities and dental care forums for its probiotic-focused approach. At this time, ProDentim is only sold through its official online platform, ensuring authenticity and access to current promotions or bundled discounts. Potential buyers are advised to avoid third-party listings and instead rely solely on for accurate details and purchasing. For those seeking a modern, non-invasive addition to their dental health routine, ProDentim offers a fresh perspective on oral care. Individuals considering this supplement should consult their dental or healthcare provider before use, especially those with preexisting conditions or allergies. SOURCE: ProDentimOfficial Website: Media Contact:ProDentim285 Northeast AveTallmadge, OH 44278United StatesPhone: 1-800-390-6035 or +1 208-345-4245Email: contact@ CONTACT: Phone: 1-800-390-6035 or +1 208-345-4245 Email: contact@
Yahoo
an hour ago
- Yahoo
47.7% of Warren Buffett's $282 Billion Portfolio Is Invested in 3 Stocks That Could Net Berkshire Hathaway $1.6 Billion in Dividends This Year
Warren Buffett's simple investing strategy propeled Berkshire Hathaway to market-beating returns since 1965. Buffett likes investing in companies that return money to shareholders through dividends, because they compound his returns more quickly. Three of Berkshire's holdings, which represent almost half of the value of its portfolio, could deliver $1.6 billion in dividend payments this year. 10 stocks we like better than Apple › Warren Buffett has been the CEO of the Berkshire Hathaway holding company since 1965. He plans to step down at the end of this year, but he will continue serving as chairman of the board. Even without the Oracle of Omaha at the helm, Buffett's successful brand of long-term investing is expected to continue. Buffett typically invests in growing companies with reliable profits and strong management teams. He especially likes companies with shareholder-friendly initiatives like dividend schemes and stock buyback programs, because they compound his returns much faster. Buffett's strategy has been so successful that a $1,000 investment in Berkshire stock in 1965 would have been worth a staggering $44.7 million at the end of 2024. The same investment in the S&P 500 would have grown to just $342,906. Berkshire holds a number of dividend-paying stocks, but three of them represent 47.7% of the total value of its $282 billion portfolio of publicly traded securities. Assuming Buffett and his team don't sell a single share in those companies, they could net the conglomerate a whopping $1.6 billion in dividends this year alone. Apple (NASDAQ: AAPL) is the $3 trillion juggernaut responsible for some of the world's most popular consumer devices including the iPhone, iPad, and Mac line of computers. Buffett and his team spent around $38 billion buying Apple shares between 2016 and 2023, and the value of that position grew to an eye-popping $170 billion heading into 2024. It accounted for more than half of the value of Berkshire's entire portfolio at that point, so Buffett and his team sold half the position last year to reduce some of the concentration risk. Apple is still Berkshire's largest holding with a 21.7% weighting in its portfolio, but the conglomerate's performance is now less susceptible to the fate of one single stock. So far this year, Berkshire earned a quarterly dividend payment of $0.25 per share from Apple on Feb. 13, and a second payment of $0.26 per share on May 15. It's likely to receive two more payments of $0.26 per share this year, bringing its total per-share payments to $1.03 in 2025. The conglomerate currently holds 300 million Apple shares, so that would translate to $309 million in dividends this calendar year. But the value of Berkshire's Apple position is currently $61 billion, so its dividend yield is just 0.5%. Cash in the bank pays a better return than that right now, but it's still a nice bonus on top of the incredible capital growth Berkshire earned in its time as an Apple shareholder. American Express (NYSE: AXP) is a global payments giant with a presence in over 200 countries. Unlike its competitors, the company operates a closed-loop ecosystem, which means it runs its own payments network, issues its own cards to consumers and businesses, and also funds the underlying lines of credit. The result is multiple revenue streams and significantly more control over its operating performance. Berkshire spent around $1.3 billion accumulating a stake in American Express during the 1990s, and it has been a cornerstone of the conglomerate's portfolio ever since. Berkshire currently owns one-fifth of the entire company, and its 151.6 million shares are currently worth $44.9 billion, which accounts for 15.9% of the value of its portfolio. So far in 2025, Berkshire has earned two quarterly dividend payments from American Express. The first was for $0.70 per share on Feb. 10, and the second was for $0.82 per share on May 9. There will likely be two more quarterly payments of $0.82 per share this year, translating to total per-share payments of $3.16 in 2025. Assuming Berkshire doesn't sell any of its 151.6 million shares, it stands to earn $479 million in dividends this year alone. That equals a yield of around 1.1%. Coca-Cola (NYSE: KO) is the world's largest beverage company. It's home to over 200 individual brands including its namesake, Schweppes, Powerade, Vitamin Water, Sprite, and Fanta, which it sells in more than 200 countries. Coca-Cola has built an incredible distribution network, which includes popular fast-food chains like McDonald's, to ensure its products are constantly in front of consumers. Buffett accumulated 400 million shares in Coca-Cola on Berkshire's behalf between 1988 and 1994, spending around $1.3 billion in total. He has never sold a share, and the position is now worth a whopping $28.5 billion, which accounts for 10.1% of the conglomerate's portfolio. Coca-Cola also paid Berkshire $776 million in dividends last year, so the investing powerhouse basically recoups its initial $1.3 billion outlay every two years on top of the incredible capital growth. Coca-Cola increased its dividend at the start of 2025, paying $0.51 per share during the first quarter. It's likely to remain at that level for the rest of the year if history is any guide, placing Berkshire on track to earn $2.04 in dividends per share in 2025. Assuming it doesn't sell any of its 400 million shares, that means the conglomerate stands to earn $816 million in payments (a yield of 2.8%). Berkshire's Coca-Cola position is one of the best examples of Buffett's investing strategy in action, as he relies on time and the magic of compounding to do the heavy lifting for him. Before you buy stock in Apple, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Apple wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $674,395!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $858,011!* Now, it's worth noting Stock Advisor's total average return is 997% — a market-crushing outperformance compared to 172% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 2, 2025 American Express is an advertising partner of Motley Fool Money. Anthony Di Pizio has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Apple and Berkshire Hathaway. The Motley Fool has a disclosure policy. 47.7% of Warren Buffett's $282 Billion Portfolio Is Invested in 3 Stocks That Could Net Berkshire Hathaway $1.6 Billion in Dividends This Year was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
